UNIGE document Scientific Article
previous document  unige:20748  next document
add to browser collection
Title

CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2

Authors
Asmuth, David M.
Goodrich, James
Cooper, David A.
Haubrich, Richard
Rajicic, Natasa
Mayer, Howard
Valdez, Hernan
Published in Journal of Acquired Immune Deficiency Syndromes. 2010, vol. 54, no. 4, p. 394-397
Abstract OBJECTIVES: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. METHODS: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. RESULTS: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). CONCLUSIONS: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.
Keywords CD4 Lymphocyte CountCD4-Positive T-Lymphocytes/drug effects/immunologyClinical Trials as TopicCyclohexanes/adverse effects/*therapeutic useDrug Resistance, ViralHIV Fusion Inhibitors/adverse effects/*therapeutic useHumansOpportunistic Infections/epidemiologyT-Lymphocytes/drug effects/virologyTime FactorsTreatment OutcomeTriazoles/adverse effects/*therapeutic use
Identifiers
PMID: 20009949
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Unité HIV (46)
Citation
(ISO format)
ASMUTH, David M. et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. In: Journal of Acquired Immune Deficiency Syndromes, 2010, vol. 54, n° 4, p. 394-397. https://archive-ouverte.unige.ch/unige:20748

180 hits

0 download

Update

Deposited on : 2012-05-23

Export document
Format :
Citation style :